Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas Bin Gao, BS, Yihua Sun, MD, Junhua Zhang, MD, Yan Ren, PhD, Rong Fang, BS,

Slides:

Advertisements

Similar presentations

Lung Adenocarcinoma with Ipsilateral Breast Metastasis: A Simple Coincidence? Hsu-Ching Huang, MD, Jen-Fan Hang, MD, Mei-Han Wu, MD, Teh-Ying Chou, MD,

Advertisements

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas Rong Fang, PhD, Chao Zheng, PhD, Yihua.

Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M Mutations Adi Gazdar, MD, Linda Robinson, MS, Dwight Oliver, MD,

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

Acquired C797S Mutation upon Treatment with a T790M-Specific Third-Generation EGFR Inhibitor (HM61713) in Non–Small Cell Lung Cancer Haa-Na Song, MD,

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Differential Diagnosis of Primary Versus Metastatic Pulmonary Adenocarcinomas Using Gene Mutation Analyses: A Case Report Yoshimasa Nakazato, MD, Ryota.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Third- Generation EGFR Tyrosine Kinase Inhibitor Alessandra Bearz, MD, Elisa.

T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis Hugo Gortais,

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR Marie.

Folate Receptor–Positive Circulating Tumor Cell Detected by LT-PCR–Based Method as a Diagnostic Biomarker for Non–Small-Cell Lung Cancer Xiaoxia Chen,

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation Vienna Ludovini, PhD,

Electronic Updates for JTO Readers

Geoffrey R. Oxnard, MD, Vincent A. Miller, MD, Mark E

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

Germline and Somatic DICER1 Mutations in a Well-Differentiated Fetal Adenocarcinoma of the Lung Leanne de Kock, B.Tech, Ismaël Bah, MD, Yingchen Wu,

Coexistence of the BRAF Mutation and EGFR Exon 20 Insertion in a Patient with Lung Adenocarcinoma Lih-Chyun Chang, MD, Kuan-Yu Chen, MD, PhD, Jin-Yuan.

Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients Carmelo Tibaldi, MD,

Ziad Thotathil, MD, FRCR, Jeremy Long, FRACP

Clinicopathologic Characteristics of the EGFR Gene Mutation in Non–small Cell Lung Cancer Anne S. Tsao, MD, Xi Ming Tang, MD, PhD, Bradley Sabloff, MD,

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

Kelsie L. Thu, BSc, Raj Chari, PhD, William W

Multiple Pulmonary Chondromas in a Young Female Patient: A Component of Carney Triad Gui-Bin Qiao, MD, PhD, Wei-Sheng Zeng, MD, Li-Jun Peng, MD, Wen-Zhao.

LKB1 Regulated Pathways in Lung Cancer Invasion and Metastasis

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Pyrosequencing Analysis of EGFR and KRAS Mutations in EUS and EBUS-Derived Cytologic Samples of Adenocarcinomas of the Lung Jos A. Stigt, MD, Nils A.

Lung Cancer and Prognosis in Taiwan: A Population-Based Cancer Registry Bing-Yen Wang, MD, Jing-Yang Huang, Ching-Yuan Cheng, MD, Ching-Hsiung Lin, MD,

Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Sai-Hong Ignatius Ou, MD, PhD,

Association between Congenital Lung Malformations and Lung Tumors in Children and Adults: A Systematic Review Arianna Casagrande, MD, Federica Pederiva,

Lung Adenocarcinomas Manifesting as Radiological Part-Solid Nodules Define a Special Clinical Subtype Ting Ye, MD, PhD, Lin Deng, MD, Shengping Wang,

Lung adenocarcinoma: Are skip N2 metastases different from non-skip?

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma Benjamin Izar, MD, PhD,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Yang Zhang, MD, Haiquan Chen, MD, PhD

Maria Q. Baggstrom, MD, Saiama N. Waqar, MD, Ananth K

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Integrative Genomic Analysis Reveals a High Frequency of LKB1 Genetic Alteration in Chinese Lung Adenocarcinomas Rong Fang, PhD, Chao Zheng, PhD, Yihua.

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

A Comprehensive Investigation of Molecular Features and Prognosis of Lung Adenocarcinoma with Micropapillary Component Yang Zhang, MD, Rui Wang, PhD,

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains Chenguang Li, MD,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

Aglaya G. Iyevleva, MD, PhD Journal of Thoracic Oncology

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Rapid Polymerase Chain Reaction-Based Detection of Epidermal Growth Factor Receptor Gene Mutations in Lung Adenocarcinomas Qiulu Pan, William Pao, Marc.

PTEN and PIK3CA Expression Is Associated with Prolonged Survival after Gefitinib Treatment in EGFR-Mutated Lung Cancer Patients Hideki Endoh, MD, PhD,

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

T4 or MI? Journal of Thoracic Oncology Volume 6, Issue 3, (March 2011)

Rapid Detection of Hotspot Mutations in Epidermal Growth Factor Receptor by Polymerase Chain Reaction Facilitates the Management of Non-small Cell Lung.

Genetic Changes in Squamous Cell Lung Cancer: A Review

Clinical Implications of Variant ALK FISH Rearrangement Patterns

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Ethnic Differences in the Management of Lung Cancer in New Zealand

Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J

EGFR Mutations in Squamous Cell Lung Cancer in Never-Smokers

Tissue Heterogeneity of EGFR Mutation in Lung Adenocarcinoma

Impact of Information on Quality of Life and Satisfaction of Non-small Cell Lung Cancer Patients: A Randomized Study of Standardized versus Individualized.

Two Rare Exon 21 EGFR Mutations in Patients Treated with Gefitinib

Robert Comis, MD, The Passing of a “Lung Man”

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas Bin Gao, BS, Yihua Sun, MD, Junhua Zhang, MD, Yan Ren, PhD, Rong Fang, BS, Xiangkun Han, BS, Lei Shen, MD, Xin-yuan Liu, PhD, William Pao, MD, Haiquan Chen, MD, Hongbin Ji, PhD Journal of Thoracic Oncology Volume 5, Issue 8, Pages 1130-1135 (August 2010) DOI: 10.1097/JTO.0b013e3181e05016 Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Sequencing analysis of tumor sample from laser capture microdissection revealed a homozygous somatic mutation of LKB1. Sequencing results show that the laser capture dissected tumor sample harbored one homozygous LKB1 deletion mutation del50L_53D (upper part) in contrast to the wild-type LKB1 from histologically normal lung from distant area (lower part). The 12-bp deletion is illustrated in the sequencing result of normal lung sample. Journal of Thoracic Oncology 2010 5, 1130-1135DOI: (10.1097/JTO.0b013e3181e05016) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Homozygous alteration of LKB1 F354L in two Chinese lung adenocarcinoma patients. Sequencing data showed that in patients 316 (A) and 370 (B), who carry a germline LKB1 F354L allele (red arrows), this allele was homozygous in their lung cancer samples. The weak signal of wild-type LKB1 in the lung tumor from patient 370 is likely due to the contaminating stromal cells. Journal of Thoracic Oncology 2010 5, 1130-1135DOI: (10.1097/JTO.0b013e3181e05016) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions